GenSight Biologics S.A.
GSGTF
$0.19
-$0.05-20.79%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.20K | 109.20K | 207.60K | 916.90K | 1.62M |
| Total Other Revenue | 740.00K | 774.50K | 816.00K | 1.01M | 1.22M |
| Total Revenue | 757.20K | 883.70K | 1.02M | 1.93M | 2.84M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 757.20K | 883.70K | 1.02M | 1.93M | 2.84M |
| SG&A Expenses | 5.96M | 6.10M | 6.29M | 6.37M | 6.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.16M | 15.28M | 17.56M | 18.59M | 19.95M |
| Operating Income | -12.40M | -14.40M | -16.53M | -16.66M | -17.11M |
| Income Before Tax | -13.54M | -14.93M | -16.44M | -15.62M | -15.13M |
| Income Tax Expenses | -5.20K | 1.00K | 7.50K | 15.30K | 22.70K |
| Earnings from Continuing Operations | -13.53 | -14.93 | -16.45 | -15.64 | -15.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.53M | -14.93M | -16.45M | -15.64M | -15.15M |
| EBIT | -12.40M | -14.40M | -16.53M | -16.66M | -17.11M |
| EBITDA | -12.22M | -14.01M | -15.92M | -15.79M | -15.96M |
| EPS Basic | -0.09 | -0.12 | -0.14 | -0.15 | -0.16 |
| Normalized Basic EPS | -0.06 | -0.07 | -0.09 | -0.09 | -0.10 |
| EPS Diluted | -0.09 | -0.12 | -0.14 | -0.15 | -0.16 |
| Normalized Diluted EPS | -0.06 | -0.07 | -0.09 | -0.09 | -0.10 |
| Average Basic Shares Outstanding | 593.35M | 533.71M | 474.07M | 428.54M | 383.02M |
| Average Diluted Shares Outstanding | 593.35M | 533.71M | 474.07M | 428.54M | 383.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |